PMID- 35890096
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220731
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 15
IP  - 7
DP  - 2022 Jun 27
TI  - Anti-Cytomegalovirus Therapy: Whether and When to Initiate, Those Are the 
      Questions.
LID - 10.3390/ph15070797 [doi]
LID - 797
AB  - Cytomegalovirus (CMV) reactivation in patients with autoimmune bullous disease 
      (AIBD) or severe drug eruption treated with immunosuppressive therapy was 
      traditionally thought to be merely an epiphenomenon of the underlying 
      immunosuppression. However, a detailed review of the clinical course of these 
      patients revealed that CMV reactivation occurs upon rapid immune recovery, which 
      is termed immune reconstitution inflammatory syndrome (IRIS), and that the timely 
      initiation of anti-CMV therapy, when combined with maintenance doses of 
      immunosuppressive agents, contributes to a rapid resolution of severe infectious 
      complications thought to be refractory to conventional immunosuppressive 
      therapies and unrelated to CMV reactivation. Thus, CMV reactivation resulting in 
      fatal outcomes (CMV-IRIS) can be prevented by the timely detection of CMV DNA or 
      antigens in the blood and by rapidly starting anti-CMV therapy while maintaining 
      immunosuppressive therapy. Anti-CMV therapy is highly recommended for patients 
      with CMV-IRIS or severe drug eruption who have risk factors for CMV reactivation 
      resulting in fatal outcomes.
FAU - Aoyama, Yumi
AU  - Aoyama Y
AUID- ORCID: 0000-0003-3701-5575
AD  - Department of Dermatology, Kawasaki Medical School, Kurashiki 701-0192, Japan.
FAU - Sugiyama, Seiko
AU  - Sugiyama S
AUID- ORCID: 0000-0001-8041-3750
AD  - Department of Dermatology, Kawasaki Medical School, Kurashiki 701-0192, Japan.
FAU - Yamamoto, Takenobu
AU  - Yamamoto T
AUID- ORCID: 0000-0002-7154-7033
AD  - Department of Dermatology, Kawasaki Medical School, Kurashiki 701-0192, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220627
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC9325238
OTO - NOTNLM
OT  - anti-CMV therapy
OT  - autoimmune bullous disease
OT  - cytomegalovirus reactivation
OT  - dipeptidyl peptidase 4 inhibitor-associated bullous pemphigoid
OT  - immune reconstitution inflammatory syndrome
COIS- The authors declare no conflict of interest.
EDAT- 2022/07/28 06:00
MHDA- 2022/07/28 06:01
PMCR- 2022/06/27
CRDT- 2022/07/27 01:38
PHST- 2022/03/31 00:00 [received]
PHST- 2022/06/23 00:00 [revised]
PHST- 2022/06/24 00:00 [accepted]
PHST- 2022/07/27 01:38 [entrez]
PHST- 2022/07/28 06:00 [pubmed]
PHST- 2022/07/28 06:01 [medline]
PHST- 2022/06/27 00:00 [pmc-release]
AID - ph15070797 [pii]
AID - pharmaceuticals-15-00797 [pii]
AID - 10.3390/ph15070797 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2022 Jun 27;15(7):797. doi: 10.3390/ph15070797.